US protection ending in 2032: Infections
As of the edition of 20 October 2026, 28 drugs have US protection that ends in 2032 in infections; 13 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
28 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Ansuvimab | Ends 2032 (computed from the first US licence) | Marketed | Emergent Biosolutions | 0 | |
| Atoltivimab | Ends 2032 (computed from the first US licence) | Marketed | Regeneron | 0 | |
| Avatrombopag | Ends 2032 (exclusivity) | Marketed | Akarx | MPL | 2 |
| Baricitinib | Ends 2032 (patent) | Marketed | Eli Lilly | JAK1, JAK2 | 4 |
| Brexucabtagene autoleucel | Ends 2032 (computed from the first US licence) | Marketed | Gilead Sciences | CD19 | 0 |
| Cabozantinib | Ends 2032 (exclusivity) | Marketed | Exelixis | KDR | 2 |
| Cobicistat | Ends 2032 (patent) | Marketed | Gilead Sciences | 0 | |
| Copanlisib | Ends 2032 (patent) | Marketed | Bayer | PIK3CA, PIK3CD | 2 |
| Dasabuvir | Ends 2032 (patent) | Marketed | AbbVie | 0 | |
| Doravirine | Ends 2032 (patent) | Marketed | Merck & Co. | 0 | |
| Duvelisib | Ends 2032 (patent) | Marketed | Secura Bio | PIK3CD, PIK3CG | 2 |
| Eculizumab | Ends 2032 (orphan exclusivity) | Marketed | AstraZeneca | C5 | 0 |
| Emtricitabine | Ends 2032 (patent) | Marketed | Gilead Sciences | 0 | |
| Estradiol | Ends 2032 (patent) | Marketed | ESR1 | 6 | |
| Gilteritinib | Ends 2032 (patent) | Marketed | Astellas | AXL, FLT3 | 2 |
| Golimumab | Ends 2032 (orphan exclusivity) | Marketed | Johnson & Johnson | TNF | 0 |
| Inebilizumab | Ends 2032 (computed from the first US licence) | Marketed | Amgen | CD19 | 1 |
| Moxidectin | Ends 2032 (exclusivity) | Marketed | Medicines Development For Global Health | 0 | |
| Neisseria meningitidis polysaccharide conjugated to tetanus toxoid | Ends 2032 (reference-product exclusivity) | Marketed | Sanofi | 0 | |
| Ombitasvir | Ends 2032 (patent) | Marketed | AbbVie | 0 | |
| Plazomicin | Ends 2032 (patent) | Marketed | Cipla | 0 | |
| Regorafenib | Ends 2032 (patent) | Marketed | Bayer | BRAF, FGFR1, FGFR2 | 8 |
| Selumetinib | Ends 2032 (exclusivity) | Marketed | AstraZeneca | MAP2K1, MAP2K2 | 4 |
| Tafasitamab | Ends 2032 (computed from the first US licence) | Marketed | Incyte | CD19 | 1 |
| Tenofovir alafenamide | Ends 2032 (patent) | Marketed | Gilead Sciences | 0 | |
| Treosulfan | Ends 2032 (exclusivity) | Marketed | Medexus Pharma | 0 | |
| Venetoclax | Ends 2032 (patent) | Marketed | AbbVie | BCL2 | 1 |
| Vonoprazan | Ends 2032 (exclusivity) | Marketed | Phathom Pharmaceuticals | ATP4A, ATP4B | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2032 in infections
In the product13 of these 28 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.